These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29761367)

  • 1. In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits.
    Sheppard JD; Cockrum PC; Justice A; Jasek MC
    Ophthalmol Ther; 2018 Jun; 7(1):157-165. PubMed ID: 29761367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye.
    Chastain JE; Sanders ME; Curtis MA; Chemuturi NV; Gadd ME; Kapin MA; Markwardt KL; Dahlin DC
    Exp Eye Res; 2016 Apr; 145():58-67. PubMed ID: 26474497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An ex vivo human aqueous humor-concentration comparison of two commercial bromfenac formulations.
    Walters TR; Smyth-Medina RJ; Cockrum PC
    Clin Ophthalmol; 2018; 12():943-947. PubMed ID: 29849449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic comparisons of bromfenac in DuraSite and Xibrom.
    Si EC; Bowman LM; Hosseini K
    J Ocul Pharmacol Ther; 2011 Feb; 27(1):61-6. PubMed ID: 21332395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits.
    Baklayan GA; Patterson HM; Song CK; Gow JA; McNamara TR
    J Ocul Pharmacol Ther; 2008 Aug; 24(4):392-8. PubMed ID: 18665811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ocular distribution of (14)C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model.
    Baklayan GA; Muñoz M
    Clin Ophthalmol; 2014; 8():1717-24. PubMed ID: 25228788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.
    Walters T; Raizman M; Ernest P; Gayton J; Lehmann R
    J Cataract Refract Surg; 2007 Sep; 33(9):1539-45. PubMed ID: 17720067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twice-Daily vs. Once-Daily Dosing with 0.075% Bromfenac in DuraSite: Outcomes from a 14-Day Phase 2 Study.
    Trattler W; Hosseini K
    Ophthalmol Ther; 2017 Dec; 6(2):277-284. PubMed ID: 28819932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits.
    Kida T; Kozai S; Takahashi H; Isaka M; Tokushige H; Sakamoto T
    PLoS One; 2014; 9(5):e96481. PubMed ID: 24796327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification.
    Bucci FA; Waterbury LD
    Curr Med Res Opin; 2011 Dec; 27(12):2235-9. PubMed ID: 21992076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery.
    Maxwell WA; Reiser HJ; Stewart RH; Cavanagh HD; Walters TR; Sager DP; Meuse PA
    J Ocul Pharmacol Ther; 2008 Dec; 24(6):593-9. PubMed ID: 19040348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits.
    Tajika T; Isowaki A; Sakaki H
    J Ocul Pharmacol Ther; 2011 Feb; 27(1):43-9. PubMed ID: 21118027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac.
    Lindstrom R; Kim T
    Curr Med Res Opin; 2006 Feb; 22(2):397-404. PubMed ID: 16466612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humor.
    Miyake K; Ogawa T; Tajika T; Gow JA; McNamara TR
    J Ocul Pharmacol Ther; 2008 Dec; 24(6):573-8. PubMed ID: 19049295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery.
    Jones BM; Neville MW
    Ann Pharmacother; 2013 Jun; 47(6):892-6. PubMed ID: 23715071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of bromfenac 0.09% QD to nepafenac 0.1% TID after cataract surgery: pilot evaluation of visual acuity, macular volume, and retinal thickness at a single site.
    Cable M
    Clin Ophthalmol; 2012; 6():997-1004. PubMed ID: 22815642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Ocular Delivery of Nepafenac by Cyclodextrin Complexation.
    Shelley H; Grant M; Smith FT; Abarca EM; Jayachandra Babu R
    AAPS PharmSciTech; 2018 Aug; 19(6):2554-2563. PubMed ID: 29948988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Solution pH on Distribution of Ophthalmically Administered Brimonidine in Posterior Ocular Tissues in Pigmented Rabbits.
    Shinno K; Kurokawa K; Kozai S; Kawamura A; Inada K; Tokushige H
    Ophthalmol Ther; 2019 Jun; 8(2):271-277. PubMed ID: 30891685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits.
    Shafiee A; Bowman LM; Hou E; Hosseini K
    J Ocul Pharmacol Ther; 2013 Nov; 29(9):812-6. PubMed ID: 23992042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular pharmacokinetics comparison between 0.2% olopatadine and 0.77% olopatadine hydrochloride ophthalmic solutions administered to male New Zealand white rabbits.
    Iyer GR; Cason MM; Womble SW; Li G; Chastain JE
    J Ocul Pharmacol Ther; 2015 May; 31(4):204-10. PubMed ID: 25775192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.